John G.F. Cleland

TL;DR: Ramipril reduces mortality and progression to resistant heart failure among patients with evidence of heart failure early after myocardial infarction and appears to be a major factor contributing to the reduction in mortality both by reducing circulatory failure and by reducing sudden death.

TL;DR: ACE-Is are widely utilized but given in lower doses than proven effective in clinical trials, and beta-Blockers are underused and given inLower doses to patients who fulfil the enrolment criteria of relevant landmark trials.

TL;DR: The HFA‐ESC convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework, and this report summarizes the group's recommendations for achieving common views on heart failureEndpoint selection.

TL;DR: In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated, it increased systolic ejection time, and it may have improved Dyspnea in the high-dose group.

TL;DR: Frequent ventricular extrasystoles, non-treatment with amiodarone, low mean arterial pressure, and a diagnosis of coronary artery disease were associated with a poor prognosis, with each of these variables providing extra predictive information independently of the others.